<DOC>
	<DOCNO>NCT02982642</DOCNO>
	<brief_summary>This study 52-weeks , multicenter , randomize , double-blind , placebo control , parallel trial carry 15 center around China . The study population include amnestic mild cognitive impairment patient ( plan total 240 ) age 55-85 gender . Participants randomly allocate 1612 capsule ( 1.14g per time , 3 time per day ) placebo 52-weeks double-blind treatment period . The primary outcome measure change baseline Alzheimer 's Disease Assessment Scale- Cognition Subscale ( ADAS-cog ) rate conversion dementia . The secondary outcome change baseline Mini-Mental State Examination ( MMSE ) , Delayed Story Recall test ( DSR ) , Alzheimer 's Disease Cooperative Study/Activities Daily Living scale adapt MCI patient ( ADCS/MCI/ADL24 ) . Safety assess observe side effect adverse reaction entire treatment period . Statistical analysis conduct accord per-protocol population intend-to-treat population safety analyze safety set .</brief_summary>
	<brief_title>Efficacy Safety 1612 Capsules aMnestic Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Patients enrol meet follow criterion [ 14 ] : 1. cognitive complaint patient family ; 2. objective evidence memory impairment , delayed story recall test ( DSR ) &lt; 12.6 ( age5064 less than15.5,6574less 12.5 , old 75 less than10 ) ; 3. normal general cognitive function , MiniMental State Examination ( MMSE ) score 24 30 ( include 30 ) ; 4. preservation activity daily live , Alzheimer 's Disease Cooperative Study/Activities Daily Living scale adapt MCI patient ( ADCS/MCI/ADL24 ) score 38 52 ; 5. cognitive disorder evidence clinical evaluation , clinical dementia rating scale=0.5 , memory domain = 0.5 ; 6. absence dementia , sufficiently impair cognitively functionally meet DSMIV criterion , 7. enough vision hear accomplishment neuropsychological test ; 8. capability read word write simple sentence ; 9. capability willingness give inform consent comply study procedure . The patient would ineligible follow condition : 1. non amnestic Mild cognitive impairment ; 2. meeting diagnostic criterion dementia ; 3. cognitive impairment result condition acute cerebral trauma , cerebral damage due lack oxygen , epilepsy vitamin deficiency , infection meningitis AIDS , significant endocrine metabolic disease , mental retardation , brain tumor , drug abuse alcohol abuse 4. significant psychiatric disease , depression , Hamilton depression scale &gt; 12 ; CT MRI scan show central nervous system infection Infarction focal lesion within 12 monthsï¼Œthe Hachinski Ischemic Scale ( HIS ) &gt; 4 ; 5. combine follow disease : diabetes ; poor control hypertension severe arrhythmia ; suffer heart infarction within 3 month ; severe asthma COPD ; severe indigestion ; gastrointestinal tract obstruction ; gastroduodenal ulcer ; 6. use cholinesterase inhibitor memantine within 1 month ; 7. history hypersensitivity treatment drug ; 8. concomitant drug potential interfere cognition ; 9. administration investigational drug ; severe impairment function kidney liver ; 10. vegetarian contraindication animal innards .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>